Dermira Inc. raised about $125 million in an upsized initial public offering (IPO) Friday, selling 7.8 million shares (NASDAQ:DERM) at a top-of-range $16 each. The skin treatment developer, which is leveraging UCB Pharma SA's tumor necrosis factor-alpha inhibitor Cimzia (certolizumab pegol) to lead its charge into the underserved dermatology market, closed down 3.4 percent, or 54 cents, at $15.46.